Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MYOVANT SCIENCES LTD.

(MYOV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
20.8(c) 20.27(c) 20.3(c) 20.2(c) 20.7(c) Last
358 062 531 606 468 707 193 718 292 157 Volume
-3.88% -2.55% +0.15% -0.49% +2.48% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 238 M - -
Net income 2022 -194 M - -
Net cash position 2022 83,3 M - -
P/E ratio 2022 -9,61x
Yield 2022 -
Sales 2023 376 M - -
Net income 2023 -169 M - -
Net Debt 2023 64,0 M - -
P/E ratio 2023 -12,9x
Yield 2023 -
Capitalization 1 906 M 1 906 M -
EV / Sales 2022 7,67x
EV / Sales 2023 5,23x
Nbr of Employees 407
Free-Float 39,3%
More Financials
Company
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary... 
More about the company
Ratings of Myovant Sciences Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MYOVANT SCIENCES LTD.
10/19PFIZER : Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from St..
AQ
10/12MYOVANT SCIENCES TO HOST SECOND FISC : 30 a.m. Eastern Time on October 26, 2021
AQ
10/11MYOVANT SCIENCES : Enzyvant's Immune System Disease Drug Gets FDA Approval
MT
10/07INSIDER SELL : Myovant Sciences
MT
09/29INSIDER SELL : Myovant Sciences
MT
09/13INSIDER SELL : Myovant Sciences
MT
09/10MYOVANT SCIENCES : And pfizer announce fda acceptance of supplemental new drug application..
AQ
09/09MYOVANT SCIENCES : Pfizer Say US FDA Accepted Supplemental New Drug Application for Myfemb..
MT
09/09MYOVANT SCIENCES : SVB Leerink Starts Myovant Sciences at Market Perform with $24 Price Ta..
MT
09/09PFIZER : Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Appl..
AQ
09/09MYOVANT, PFIZER : FDA to Review Myfembree for Endometriosis Pain
DJ
09/01MYOVANT SCIENCES : to Participate in the 2021 Baird Global Healthcare Conference
AQ
08/19MYOVANT SCIENCES : MYOV) sees Significant Insider buy Reversing Trend of Selling over Last..
MT
08/18INSIDER TRENDS : 90-Day Buying Trend Extended with Insider Purchase of Myovant Sciences St..
MT
08/13MYOVANT SCIENCES : Names Uneek Mehra as Chief Financial, Business Officer
MT
More news
News in other languages on MYOVANT SCIENCES LTD.
10/19PFIZER : présente de nouvelles données autour du relugolix
10/11Le médicament d'Enzyvant contre les maladies du système immunitaire est approuvé par la..
10/07VENTE D'INITIÉS : Myovant Sciences
09/29VENTE D'INITIÉS : Myovant Sciences
09/13VENTE D'INITIÉS : Myovant Sciences
More news
Analyst Recommendations on MYOVANT SCIENCES LTD.
More recommendations
Chart MYOVANT SCIENCES LTD.
Duration : Period :
Myovant Sciences Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYOVANT SCIENCES LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 20,70 $
Average target price 29,80 $
Spread / Average Target 44,0%
EPS Revisions
Managers and Directors
David C. Marek Chief Executive Officer & Director
Uneek Mehra Chief Financial & Business Officer
Myrtle S. Potter Chairman
Juan Camilo Arjona Ferreira Chief Medical Officer
Jeffrey D. Nornhold Senior VP-Pharmaceutical Operations & Development
Sector and Competitors
1st jan.Capi. (M$)
MYOVANT SCIENCES LTD.-25.05%1 906
MODERNA, INC.225.04%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.42.23%48 194
SEAGEN INC.-0.71%31 811
CELLTRION, INC.-39.42%25 446